Biofrontera Inc. (BFRI)
(Delayed Data from NSDQ)
$1.28 USD
0.00 (0.00%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.28 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Price, Consensus and EPS Surprise
BFRI 1.28 0.00(0.00%)
Will BFRI be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BFRI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BFRI
Entrada Therapeutics, Inc. (TRDA) Tops Q2 Earnings and Revenue Estimates
Lineage Cell (LCTX) Reports Q2 Loss, Tops Revenue Estimates
BFRI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings Estimates
Other News for BFRI
Why Xperi Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Benchmark Co. Reaffirms Their Buy Rating on Biofrontera (BFRI)
Biofrontera Inc. (BFRI) Q2 2024 Earnings Call Transcript
Biofrontera GAAP EPS of -$0.05 beats by $0.67, revenue of $7.84M beats by $0.38M
Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update